Below is the market scale and growth rate in recent years and near future for our project.
|Annual growth rate||Major drugs|
|Multiple Sclerosis||1||14.8||5.2%||Dimethyl Fumarate|
|Dry AMD||8.5||2.1||8.0%||No drug|
Painful Diabetic Neuropathy (PDN) segment accounts for the largest share (47%) of the Neuropathic pain (NP) market. The first line drug for Trigeminal Neuralgia (TN), Chemotherapy-induced pain, and Painful diabetic neuropathy (PDN) is Carbamazepine, Duloxetine, Pregabalin, respectively.
However, a review of recent clinical trials suggests that treatments in clinical practice, only offers about a third of patients with around 50% pain relief, and with troublesome side effects (PMID 17920770). While opiates are heavily overprescribed to the point of national crisis, they are of little therapeutic value for Neuropathic pain treatment.
The prevalence of PDN is 2% of the US population, and the number will continue to rise. Most common forms of NP (excluding back pain) are listed below: